Search Result

Results for "

AML

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ack1 (1) ADC Antibody (3) ADC Payload (4) Akt (9) AMPK (4) Antibiotic (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (154) Arenavirus (1) Atg8/LC3 (4) Aurora Kinase (3) Autophagy (10) Bacterial (4) Bcl-2 Family (14) Bcr-Abl (7) Biochemical Assay Reagents (3) BMI1 (1) Btk (1) c-Fms (1) c-Kit (12) c-Myc (6) Casein Kinase (6) Caspase (12) CD3 (3) CDK (22) Ceramidase (1) Checkpoint Kinase (Chk) (1) ClpP (1) CMV (1) Complement System (1) CRM1 (1) Cuproptosis (1) CXCR (3) Cytochrome P450 (1) Deubiquitinase (3) Dihydroorotate Dehydrogenase (9) Discoidin Domain Receptor (1) DNA Alkylator/Crosslinker (4) DNA Methyltransferase (7) DNA/RNA Synthesis (16) Drug Derivative (1) Drug Metabolite (8) Drug-Linker Conjugates for ADC (1) DYRK (2) E1/E2/E3 Enzyme (5) E3 Ligase Ligand-Linker Conjugates (6) Endogenous Metabolite (5) Epigenetic Reader Domain (32) ERK (3) Estrogen Receptor/ERR (4) Eukaryotic Initiation Factor (eIF) (1) FAK (1) Fat Mass and Obesity-associated Protein (FTO) (5) Ferroptosis (2) FGFR (5) FLT3 (88) Fluorescent Dye (1) GSK-3 (5) HBV (1) HDAC (15) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (5) Histone Demethylase (9) Histone Methyltransferase (4) HIV (1) HSP (2) IFNAR (3) IKZF Family (3) IMPDH (1) Interleukin Related (4) IRAK (7) Isocitrate Dehydrogenase (IDH) (8) Isotope-Labeled Compounds (2) JAK (10) Keap1-Nrf2 (1) Kinesin (3) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (7) LPL Receptor (1) MAGL (1) MARK (2) MDM-2/p53 (6) MEK (1) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (2) METTL3 (7) Microtubule/Tubulin (1) Mitochondrial Metabolism (5) Mitophagy (1) MMP (2) MNK (3) Molecular Glues (8) mTOR (3) MyD88 (4) NADPH Oxidase (1) NF-κB (7) Nucleoside Antimetabolite/Analog (4) Oxidative Phosphorylation (3) P-glycoprotein (4) p38 MAPK (4) p62 (3) p97 (3) PACAP Receptor (2) Parasite (2) PARP (6) PDGFR (10) PERK (1) Phosphatase (2) Phosphodiesterase (PDE) (2) PI3K (5) Pim (6) PIN1 (1) PKC (3) Polo-like Kinase (PLK) (1) PROTAC Linkers (3) PROTACs (33) Proteasome (1) Pyroptosis (2) Radionuclide-Drug Conjugates (RDCs) (1) Ras (1) Reactive Oxygen Species (ROS) (8) Reference Standards (9) RET (2) Ribosomal S6 Kinase (RSK) (1) RUNX (2) Salt-inducible Kinase (SIK) (3) Scavenger Receptor Class B type I (SR-BI） (1) SF3B1 (1) SHP2 (3) Sirtuin (1) Small Interfering RNA (siRNA) (1) Sodium Channel (1) Src (2) STAT (15) TET Protein (3) Tim3 (1) TNF Receptor (3) Topoisomerase (2) Transferrin Receptor (1) Transmembrane Glycoprotein (10) Trk Receptor (1) VEGFR (4) Wee1 (1) Wnt (1) Xanthine Oxidase (1) YTHDF (1) β-catenin (1)
By Research Areas:	Cancer (394) Cardiovascular Disease (5) Endocrinology (1) Infection (12) Inflammation/Immunology (33) Metabolic Disease (7) Neurological Disease (6)
Oligonucleotides:	CpG ODNs (2)

406

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148422

Rohinitib 1 Publications Verification	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

HY-122623A

DB818 dihydrochloride	Apoptosis	Cancer
DB818 dihydrochloride is the dihydrochloride salt form of DB818 (HY-122623). DB818 dihydrochloride is an inhibitor for Homeobox A9 (HOXA9). DB818 dihydrochloride reduces the formation of HOXA9-DNA complexes, inhibits the growth and induces apoptosis in AML cell lines OCI/AML3, MV4-11, and THP-1 .

HY-P99390

Tepoditamab MCLA 117	CD3 Interleukin Related IFNAR TNF Receptor	Inflammation/Immunology Cancer
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .

HY-P9983

Lintuzumab SGN-33; HuM-195	Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .

HY-P990612

*LGN-523 (AML-01)* AML-01	Transmembrane Glycoprotein	Inflammation/Immunology
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-175274

MolPort-002-705-878	FLT3	Cancer
MolPort-002-705-878 is a highly selective FMS-like tyrosine kinase 3 (FLT3) inhibitor with a binding affinity of −11.33 kcal/mol. MolPort-002-705-878 inhibits the proliferation of FLT3-mutated acute myeloid leukemia (AML) cells. MolPort-002-705-878 is promising for research of FLT3-mutated AML .

HY-162265

UCM-13369	Apoptosis	Cancer
UCM-13369 (Compound 4b) is a NPM1 inhibitor. UCM-13369 downregulates the pathway associated with mutant NPM1 C+, and specifically recognizes the C-end DNA-binding domain of NPM1 C+. UCM-13369 induces apoptosis in AML cell lines and primary cells, that can be used for the research of AML .

HY-110071

APcK110	c-Kit	Cancer
APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis .

HY-P991665

MEN1112 OBT357NF; OBT357	Transmembrane Glycoprotein	Cancer
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC₅₀=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .

HY-117690A

dBRD9 dihydrochloride	PROTACs Epigenetic Reader Domain	Cancer
dBRD9 dihydrochloride is a selective BRD9 PROTAC degrader. dBRD9 dihydrochloride inhibits proliferation of AML cell lines .

HY-157481

HDAC1-IN-6	HDAC	Cancer
HDAC1-IN-6 (compound 1) is an inhibitor of HDAC1 and 11, with an IC₅₀ of 1.9 μM and 1.6 μM, respectively. HDAC1-IN-6 induces differentiation in AML cells .

HY-161779

PLX-3618	Molecular Glues Epigenetic Reader Domain Apoptosis	Cancer
PLX-3618 is a molecular glue, that degrades BRD4 with DC₅₀ of 12.2 nM. PLX-3618 promotes polyubiquitination and subsequent proteasomal degradation of BRD4 by recruiting of the E3 ligase substrate receptor, DCAF11. PLX-3618 inhibits the proliferation of various cancer cells, induces apoptosis in AML cells. PLX-3618 exhibits antitumor activity against AML in mouse models .

HY-162293

CDK8-IN-14	CDK	Cancer
CDK8-IN-14 (compound 12) inhibits CDK8 with an IC₅₀ value of 39.2 nM and has anti-AML cell proliferation activity (molm-13 GC50 = 0.02±0.01μM, MV4-11 GC50 = 0.03±0.01μM) .

HY-138831

AES-350	HDAC Apoptosis	Cancer
AES-350 is a potent and orally active HDAC6 inhibitor with an IC₅₀ and a K_i of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC₅₀ values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research .

HY-173444

HDAC11-IN-3	HDAC Transferrin Receptor Apoptosis Ferroptosis	Cancer
HDAC11-IN-3 (Compound A9) is a selective HDAC11 inhibitor (IC₅₀: 4.1 nM). HDAC11-IN-3 has inhibitory effects on U937 and OCI-AML2 acute myeloid leukemia (AML) cell lines (IC₅₀: 10 μM). HDAC11-IN-3 has significant anti-AML activity, inducing apoptosis, cell cycle arrest, and differentiation. HDAC11-IN-3 upregulates the iron transporters transferrin (TF) and transferrin receptor (TFRC), and activates the p62-Keap1-Nrf2-HMOX1 pathway, which together lead to increased intracellular iron levels and induce ferroptosis in AML cells. HDAC11-IN-3 can be used alone or in combination with Cytarabine (HY-13605) for AML research .

HY-P991294

MGTA-117 Antibody	ADC Antibody	Cancer
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .

HY-161920

SIRT3-IN-1	Sirtuin Apoptosis	Cancer
SIRT3-IN-1 (compound 17f) is a SIRT3 inhibitor, with IC₅₀ of 0.043 μM. SIRT3-IN-1 can be used in the research of acute leukemia (AML) .

HY-177467

P0064	Others	Cancer
P0064 is a selective inhibitor targeting the PR domain of PRDM16. P0064 selectively reduces proliferation and survival of FLT3-ITD+ leukemia cells. P0064 is promising for research of acute myeloid leukemia (AML) .

HY-W773779

GSK3-IN-9	GSK-3	Neurological Disease Metabolic Disease Cancer
GSK3-IN-9 (Compound 0713) is a selective glycogen synthase kinase 3 (GSK3) inhibitor. GSK3-IN-9 Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder .

HY-112037A

IACS-010759 hydrochloride 15+ Cited Publications IACS-10759 hydrochloride	Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis	Cancer
IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research .

HY-112037

IACS-010759 15+ Cited Publications IACS-10759	Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis	Cancer
IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research .

HY-173320

HEMTAC WEE1 degrader-1	Wee1 HSP	Cancer
HEMTAC WEE1 degrader-1 is a HSP90-mediated targeting chimera (HEMTAC) degrader of WEE1 (HSP90 enzyme inhibitory activity is IC₅₀: 16.76 nM). HEMTAC WEE1 degrader-1 promotes the ubiquitination and degradation of WEE1. HEMTAC WEE1 degrader-1 blocks the G2/M cell cycle. HEMTAC WEE1 degrader-1 has anticancer activity in acute myeloid leukemia (AML) patient-derived xenograft (PDX) models. HEMTAC WEE1 degrader-1 can be used in AML research. (Pink: HSP90 binder; Blue: WEE1 ligand; Black: linker) .

HY-101025

Nrf2-IN-1 5+ Cited Publications	Keap1-Nrf2	Cancer
Nrf2-IN-1 is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2-IN-1 is developed for the research of acute myeloid leukemia (AML) .

HY-142161

ABD957 1 Publications Verification	MAGL	Cancer
ABD957 is a potent and selective covalent inhibitor of the ABHD17 family of depalmitoylases, with an IC₅₀ of 0.21 μM for ABHD17B. ABD957 can block N-Ras signaling and the growth of NRAS-mutant AML cells .

HY-162265A

UCM-13369 dihydrochloride	Apoptosis	Cancer
UCM-13369 (Compound 4b) is a NPM1 inhibitor. UCM-13369 downregulates the pathway associated with mutant NPM1 C+, and specifically recognizes the C-end DNA-binding domain of NPM1 C+. UCM-13369 induces apoptosis in AML cell lines and primary cells. UCM-13369 can be used for leukemia research .

HY-171792

BMS-986497 ORM-6151	Transmembrane Glycoprotein	Cancer
BMS-986497 (ORM-6151) is a CD33-targeted antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells, inducing GSPT1 protein degradation. BMS-986497 is promising for research of acute myeloid leukemia (AML) .

HY-161615

PROTAC ATR degrader-2	Apoptosis PROTACs	Cancer
PROTAC ATR degrader-2 (Compound 8i) is a PROTAC degrader for ATR, through of . PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ of 22.9 and 34.5 nM. APROTAC ATR degrader-2 induces apoptosis, inhibits proliferations of AML cells. PROTAC ATR degrader-2 exhibits good pharmacokinetics charachers and antitumor efficacy against AML in mouse model. (Pink: ATR ligand (HY-161616); Blue:E3 ligase ligand Lenalidomide (HY-A0003); Black: linker)

HY-134557

GS87	GSK-3	Cancer
GS87 is a highly specific and potent GSK3 inhibitor with IC₅₀s of 415nM and 521nM for GSK3α and GSK3β, respectively. GS87 induces differentiation of acute myeloid leukemia (AML) cell lines by effectively activating GSK3-dependent signaling components including MAPK signaling. GS87 modulates key GSK3 target proteins involved in cell proliferation and differentiation more effectively than Lithium and SB415285 (SB). GS87 has the potential for acting as a differentiation agent for non-promyelocytic AML research .

HY-N0564

Notopterol 2 Publications Verification	Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML) .

HY-175886

FTO ligand-1	Ligands for Target Protein for PROTAC Fat Mass and Obesity-associated Protein (FTO)	Cancer
FTO ligand-1 is a FTO ligand for FTO PROTAC degrader FP54 (HY-175885). FTO ligand-1 can inhibit cell proliferation and block the FP54-induced FTO degradation. FTO ligand-1 can be used for research of cancer, such as acute myeloid leukemia (AML) .

HY-N10221

Petromurin C	Apoptosis	Cancer
Petromurin C is a bisindolylbenzenoid compound isolated from the ascostromata of Petromycesmuricatus. Petromurin C induces protective autophagy and apoptosis in FLT3-ITD-positive AML .

HY-174844

p97-IN-1	p97	Cancer
p97-IN-1 is an orally active p97 inhibitor (IC₅₀ = 26 nM). p97-IN-1 can significantly inhibit the proliferation of tumor cells. p97-IN-1 can be used for research on acute myeloid leukemia (AML) .

HY-175473

HI042	FLT3 Apoptosis	Cancer
HI042 is a FMS-like Tyrosine Kinase 3 (FLT3) inhibitor. HI042 shows IC₅₀ values of 0.62 μM for MOLM-13, 0.33 μM for MV4-11, and 0.89 μM for OCI-AML3 cells. HI042 selectively reduces the viability of FLT3-internal tandem duplication (FLT3-\|TD) mutations-positive cell lines, induces apoptosis, disrupts cell cycle progression, and diminishes the clonogenic potential. HI042 can be used for the research of acute myeloid leukemia (AML) .

HY-149474

HDAC-IN-63	FLT3 HDAC Apoptosis	Cancer
HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor (IC₅₀: 0.844 and 30.0 nM for FLT3 and HDAC1 respectively). HDAC-IN-63 inhibits MV4-11 cell proliferation (IC₅₀: 92 nM. HDAC-IN-63 induces apoptosis and arrests cell cycle in MV4-11 cells. HDAC-IN-63 can be used for research of acute myeloid leukemia (AML) .

HY-160415

WD6305 2 Publications Verification	PROTACs Apoptosis METTL3	Cancer
WD6305 is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 has DC₅₀ values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 inhibits m ⁶A modification and proliferation of AML cells, and induces apoptosis. WD6305 has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))

HY-172931

DEG-35	Molecular Glues Casein Kinase IKZF Family	Cancer
DEG-35 is a CRBN-dependent, dual IKZF2 and CK1α molecule glue degrader, with DC₅₀ values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. DEG-35 activates the p53 apoptosis pathway. DEG-35 can be used in the research for Acute Myeloid Leukemia (AML) .

HY-164460

AZD1897	Pim	Cancer
AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC₅₀ values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways .

HY-W965550

Apoptosis inducer 40	Apoptosis	Cancer
Apoptosis inducer 40 is an apoptosis inducer. Apoptosis inducer 40 exhibits potent cytotoxic effects against jurkat and NB4 cells with IC₅₀ values of 4.5 μM and 3.6μM. Apoptosis inducer 40 induces apoptosis and arrests cell cycle. Apoptosis inducer 40 can be used for the research of cancer, such as acute myeloid leukemia (AML) .

HY-100688

ML390 1 Publications Verification	Dihydroorotate Dehydrogenase	Cancer
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .

HY-101150

DGN462	DNA Alkylator/Crosslinker ADC Payload	Cancer
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-101150A

sulfo-DGN462 sodium	DNA Alkylator/Crosslinker ADC Payload	Cancer
sulfo-DGN462 sodium is degraded to DGN462 in culture medium and plasma. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML) .

HY-162367

FLT3/CHK1-IN-2	FLT3 Checkpoint Kinase (Chk)	Cancer
FLT3/CHK1-IN-2 (Compound 30) is a dual inhibitor of FLT3 and CHK1, with IC₅₀s of 25.63, 16.39, 22.80 nM for CHK1, FLT3-WT, and FLT-D835Y respectively. FLT3/CHK1-IN-2 has favorable oral PK properties and kinase selectivity. FLT3/CHK1-IN-2 can be used for research of acute myeloid leukemia (AML) .

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Transmembrane Glycoprotein	Cancer
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .

HY-P991558

RO-5429083 RG-7356	Transmembrane Glycoprotein	Cancer
RO-5429083 is a humanized monoclonal antibody inhibitor targeting CD44. RO-5429083 can be used for acute myeloid leukemia (AML) and solid tumors research .

HY-107458

AP23848	c-Kit	Cancer
AP23848 is an ATP-dependent kinase inhibitor that effectively and selectively targets the Kit activation loop mutation both in vitro and in vivo, showing anti-tumor activity. AP23848 can inhibit the phosphorylation of the activated Kit mutation and tumor growth in mice, making it suitable for targeting diseases with the D816V mutation, such as systemic mastocytosis (SM) and acute myeloid leukemia (AML) research .

HY-156759

METTL3-IN-5	METTL3	Cancer
METTL3-IN-5 (Compound 13) is a METTL3 inhibitor. METTL3-IN-5 inhibits MOLM-13 growth with an IC₅₀ less than 2 μM. METTL3-IN-5 has weak hERG inhibitory activity (IC₅₀ >30 μM). METTL3-IN-5 can be used for AML research .

HY-175040

PROTAC FLT-3 degrader 5	PROTACs Molecular Glues FLT3 IKZF Family	Cancer
PROTAC FLT-3 degrader 5 is a FLT3 PROTAC degrader (DC₅₀ = 1.2 nM). PROTAC FLT-3 degrader 5 functions as a molecular glue to degrade cereblon substrates GSPT1 and IKZF1/3. PROTAC FLT-3 degrader 5 exhibits antiproliferative activity against drug-resistant acute myeloid leukemia (AML) cells and is potentially useful in AML research. (Pink: FLT3/GSPT1/IKZF1/3 ligand: (HY-169374); Blue: Thalidomide: (HY-14658); Black: linker; Thalidomide + linker: (HY-W1123823)) .

HY-160415A

WD6305 TFA 2 Publications Verification	PROTACs Apoptosis METTL3	Cancer
WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 TFA has DC₅₀ values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 TFA inhibits m ⁶A modification and proliferation of AML cells, and induces apoptosis. WD6305 TFA has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))

HY-101266B

Milademetan tosylate hydrate 5 Publications Verification DS-3032b; DS-3032 tosylate hydrate	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis .

HY-101266

Milademetan 5 Publications Verification DS-3032	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis .

Cat. No.	Product Name	Type

HY-16700G

PNU-159682 (GMP)	Fluorescent Dye
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.

Cat. No.	Product Name	Type

HY-16700G

PNU-159682 (GMP)	Biochemical Assay Reagents
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.

Cat. No.	Product Name	Target	Research Area

HY-P11288A

ANT308 TFA	PACAP Receptor Apoptosis	Cancer
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P11076

CP-EPS8-NLS	Complement System	Cancer
CP-EPS8-NLS is a peptide with anti-AML property. CP-EPS8-NLS interferes with EPS8-associated signaling and exerts anti-AML activity in various AML cell types. CP-EPS8-NLS has potent antitumor activity in xenograft tumor models. CP-EPS8-NLS downregulates EPS8 expression and its downstream pathway .

HY-P11288

ANT308	PACAP Receptor Apoptosis	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

Cat. No.	Product Name	Target	Research Area

HY-P99390

Tepoditamab MCLA 117	CD3 Interleukin Related IFNAR TNF Receptor	Inflammation/Immunology Cancer
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .

HY-P9983

Lintuzumab SGN-33; HuM-195	Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Transmembrane Glycoprotein	Cancer
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .

HY-P990002

Anti-Mouse CD117/c-Kit Antibody (2B8)	c-Kit	Inflammation/Immunology Cancer
Anti-Mouse CD117/c-Kit Antibody (2B8) is an IgG2b antibody, targeting to mouse CD117/c-Kit. Anti-Mouse CD117/c-Kit Antibody (2B8) reacts with mouse c-Kit (also known as CD117), which is expressed on hematopoietic progenitor cells, mast cells, and acute myeloid leukemia (AML) cells. Anti-Mouse CD117/c-Kit Antibody (2B8) can be used for the detection of flow cytometry, immunofluorescence and immunohistochemistry in cancer and inflammation .

HY-P99971

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990612

*LGN-523 (AML-01)* AML-01	Transmembrane Glycoprotein	Inflammation/Immunology
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991665

MEN1112 OBT357NF; OBT357	Transmembrane Glycoprotein	Cancer
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC₅₀=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .

HY-P991294

MGTA-117 Antibody	ADC Antibody	Cancer
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .

HY-P991558

RO-5429083 RG-7356	Transmembrane Glycoprotein	Cancer
RO-5429083 is a humanized monoclonal antibody inhibitor targeting CD44. RO-5429083 can be used for acute myeloid leukemia (AML) and solid tumors research .

HY-P991648

CSL-360	Interleukin Related	Cancer
CSL-360 is a chimeric unconjugated IgG1 monoclonal antibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research .

HY-P990164

Anti-Mouse RGMb Antibody (307.9D1)	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-Mouse RGMb Antibody (307.9D1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse RGMb. Anti-Mouse RGMb Antibody (307.9D1) blocks RGMb binding to PD-L2. Anti-Mouse RGMb Antibody (307.9D1) can be used for the researches of cancer inflammation and immunology, such as acute myeloid leukemia (AML) and graft versus-host disease (GVHD) .

HY-P99488

Briquilimab JSP-191; AMG-191	c-Kit	Inflammation/Immunology Cancer
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .

HY-P991669

IGN523	Caspase Apoptosis	Cancer
IGN523 is an anti-CD98 antibody (hCD98, K_D = 0.55 nM). IGN523 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, lysosomal membrane permeabilization, and inhibition of essential amino acid transport, ultimately leading to caspase-3 and caspase-7-mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in multiple tumor xenograft models. IGN523 is useful in the research of non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and other cancers. .

HY-P991656

LY-2624587	CXCR Apoptosis p38 MAPK Akt	Cancer
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .

HY-P991425

AT-1413	Transmembrane Glycoprotein	Cancer
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99395

Talacotuzumab 1 Publications Verification JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P99912

Emerfetamab AMG-673	Inhibitory Antibodies	Inflammation/Immunology
Emerfetamab is an anti-CD3E/CD33 monoclonal antibody .

HY-P99014

Cusatuzumab 1 Publications Verification ARGX-110	Apoptosis	Inflammation/Immunology Cancer
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-P990786

Anti-FLT3 Antibody (AGS62P)	FLT3 ADC Antibody	Cancer
Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia .

HY-P991517

BI-836858	Transmembrane Glycoprotein	Cancer
BI-836858 is a fully humanized IgG1 anti-CD33 monoclonal antibody. BI-836858 is Fc-engineered for increased binding to FcγRIIIa (CD16). BI-836858 has antibody-dependent cellular cytotoxicity (ADCC) activities. BI-836858 can be used for the study of acute myeloid leukemia (AML) .

HY-P99916

Emirodatamab AMG-427	FLT3	Inflammation/Immunology
Emirodatamab is an anti-CD3E/FLT3 monoclonal antibody .

HY-P99910

Eluvixtamab AMG-330	Inhibitory Antibodies	Inflammation/Immunology
Eluvixtamab is an anti-CD3E/CD33 monoclonal antibody .

HY-P99394

Talquetamab JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-P99272

Ulocuplumab 1 Publications Verification BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0564

Notopterol 2 Publications Verification	Neurological Disease Classification of Application Fields Source classification Coumarins Phenylpropanoids Kleinia odora (Forssk.) DC. Umbelliferae Plants Inflammation/Immunology Disease Research Fields	Apoptosis
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML) .

HY-129099A

N-Desmethyltamoxifen hydrochloride	Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite
N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .

HY-13680

Meisoindigo 1 Publications Verification Dian III; N-Methylisoindigotin; Natura-α	Alkaloids other families Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Cancer	Apoptosis
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-N0071

Crotonoside Isoguanosine	Alkaloids Classification of Application Fields Other Alkaloids Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-N10221

Petromurin C	Alkaloids Monophenols Microorganisms Classification of Application Fields Source classification Phenols Disease Research Fields Indole Alkaloids Cancer	Apoptosis
Petromurin C is a bisindolylbenzenoid compound isolated from the ascostromata of Petromycesmuricatus. Petromurin C induces protective autophagy and apoptosis in FLT3-ITD-positive AML .

HY-N0564R

Notopterol (Standard)	Source classification Coumarins Phenylpropanoids Kleinia odora (Forssk.) DC. Umbelliferae Plants	Reference Standards Apoptosis
Notopterol (Standard) is the analytical standard of Notopterol. This product is intended for research and analytical applications. Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML) .

HY-129099

N-Desmethyltamoxifen	Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite
N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .

HY-129099AR

N-Desmethyltamoxifen hydrochloride (Standard)	Alkaloids Other Alkaloids Source classification Endogenous metabolite	Reference Standards PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite
N-Desmethyltamoxifen (hydrochloride) (Standard) is the analytical standard of N-Desmethyltamoxifen (hydrochloride). This product is intended for research and analytical applications. N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].

HY-13680R

Meisoindigo (Standard)	Alkaloids other families Source classification Plants Indole Alkaloids	Apoptosis
Meisoindigo (Standard) is the analytical standard of Meisoindigo. This product is intended for research and analytical applications. Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-N10079

Suchilactone Jatrophan	Polygala chinensis Linnaeus Source classification Polygalaceae Lignans Phenylpropanoids Plants	SHP2
Suchilactone (Jatrophan) is a lignan extracted from Monsonia angustifolia E.Mey. Suchilactone binds to SHP2 and inhibits SHP2 activation, thereby inhibiting ERK-mediated cell proliferation. Suchilactone can be ued in acute myeloid leukaemia (AML) .

HY-N12641

Ardisianone	Quinones Source classification Benzene Quinones Plants Primulaceae	Apoptosis Pyroptosis
Ardisianone is a component with an alkyl benzoquinone structure that can be isolated from Ardisia virens Kurz and Ardisia compressa tea extract. Ardisianone exhibits potent antileukemic activity, particularly against HL-60 cells, with IC₅₀ values of 1.87 μM (24 h) and 1.67 μM (48 h). Ardisianone induces caspase-dependent apoptosis and triggers pyroptosis. Ardisianone can be used for the study of acute myeloid leukemia (AML) .

HY-N10264

Avrainvillamide (+)-Avrainvillamide; CJ-17,665	Infection Alkaloids Microorganisms Pyrrole Alkaloids Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Antibiotic
Avrainvillamide ((+)-Avrainvillamide) is a naturally occurring alkaloid with antiproliferative effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many different human tumors. Avrainvillamide affects cell biology both by directly binding NPM1 and Crm1 as well as by inhibiting the association of these proteins with certain native cellular partners. Avrainvillamide, an antibiotic, inhibits growth of multi-agent resistant Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, with MICs of 12.5, 12.5 and 25 μg/ml, respectively .

HY-107417

Hypothemycin	Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively .

Cat. No.	Product Name	Chemical Structure

HY-50907S

ABT-737-d8

ABT 737-d₈ is the deuterium labeled ABT-737. ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

HY-18767S2

Ivosidenib-13C5
Ivosidenib- ¹³C₅ (AG-120- ¹³C₅) is ¹³C labeled Ivosidenib. Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .

HY-18767S3

Ivosidenib-d5
Ivosidenib-d₅ (AG-120-d₅) is deuterium labeled Ivosidenib. Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P84458

	RUNX1 Antibody (YA4155) AML1; CBFA2; EVI-1; AMLCR1; PEBP2aB; AML1-EVI-1; RUNX1	WB, ICC/IF, ELISA	Human
	RUNX1 Antibody (YA4155) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RUNX1.

HY-P80888

	RUNX1/2/3 Antibody (YA086) RUNX1; AML1; RUNX2; OSF2; RUNX3; CBFA3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	RUNX2 Antibody (YA086) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RUNX2.

HY-P86399

	RUNX2 Antibody (YA6091) RUNX2; AML3; CBFA1; OSF2; PEBP2A; Runt-related transcription factor 2; Acute myeloid leukemia 3 protein; Core-binding factor subunit alpha-1; CBF-alpha-1; Oncogene AML-3Osteoblast-specific transcription factor 2; OSF-2; Polyomavirus enhancer-binding protein 2 alpha A subunit; PEA2-alpha A; PEBP2-alpha A; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core-binding factor alpha A subunit	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	RUNX2 Antibody (YA6091) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RUNX2.

HY-P81396

	RUNX3 Antibody (YA1141) AML2; CBFA3; PEBP2aC; FLJ34510; MGC16070	IHC-P	Human
	RUNX3 Antibody (YA1141) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RUNX3.

HY-P84556

	RUNX3 Antibody (YA4253) AML2; CBFA3; PEBP2aC; FLJ34510; MGC16070	IHC-P, ICC/IF, FC, ELISA	Human, Mouse
	RUNX3 Antibody (YA4253) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to RUNX3.

HY-P85360

	RUNX1 Antibody (YA5052) RUNX1; AML1; CBFA2; Runt-related transcription factor 1; Acute myeloid leukemia 1 protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B; PEBP2-alpha	WB, ICC/IF, ELISA	Human
	RUNX1 Antibody (YA5052) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to RUNX1.

HY-P86201

	RUNX1 Antibody (YA5893) RUNX1; AML1; CBFA2; Runt-related transcription factor 1; Acute myeloid leukemia 1 protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B; PEBP2-alpha	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	RUNX1 Antibody (YA5893) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RUNX1.

HY-P82334

	Aly Antibody (YA2079) ALYREF; ALY; BEF; THOC4; THO complex subunit 4; Tho4; Ally of AML-1 and LEF-1; Aly/REF export factor; Transcriptional coactivator Aly/REF; bZIP-enhancing factor BEF	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	Aly Antibody (YA2079) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aly.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-150725

ODN 1585		CpG ODNs
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

HY-150725C

ODN 1585 sodium		CpG ODNs
ODN 1585 sodium is a potent inducer of IFN and TNFα production. ODN 1585 sodium is a potent stimulator of NK (natural killer) function. ODN 1585 sodium increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 sodium induces regression of established melanomas in mice. ODN 1585 sodium can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 sodium can be used as a vaccine adjuvant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks